Table 2.
Change of adiposity markers during follow-up by any antidepressant use prior to baseline and during follow-up.
| Change in adiposity markers during follow-up | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Crude change | Model 1 | Model 2 | Model 3 | ||||||
| Mean (SD) | βa | (95%CI) | β | (95%CI) | β | (95%CI) | β | (95%CI) | |
| Body Mass Index [kg/m2] (n = 2462) | |||||||||
| Antidepressants prior to baseline | |||||||||
| Number of compounds | — | −0.01 | (−0.07, 0.04) | −0.08* | (−0.14, −0.02) | −0.12*** | (−0.18, −0.06) | −0.12*** | (−0.19, −0.05) |
| Antidepressants during follow-up | |||||||||
| Any antidepressants | 0.9 (2.2) | 0.35*** | (0.19, 0.50) | 0.42*** | (0.25, 0.59) | 0.34*** | (0.16, 0.52) | 0.32*** | (0.13, 0.50) |
| No antidepressants (ref.) | 0.6 (1.7) | 0 (ref.) | — | 0 (ref.) | — | 0 (ref.) | — | 0 (ref.) | — |
| Waist circumference [cm] (n = 2475) | |||||||||
| Antidepressants prior to baseline | |||||||||
| Number of compounds | — | 0.06 | (−0.19, 0.30) | −0.19 | (−0.46, 0.08) | −0.28 | (−0.56, 0.00) | −0.28* | (−0.56, −0.01) |
| Antidepressants during follow-up | |||||||||
| Any antidepressants | 4.6 (7.3) | 1.39*** | (0.73, 2.05) | 1.52*** | (0.79, 2.25) | 1.29** | (0.52, 2.06) | 1.23** | (0.44, 2.01) |
| No antidepressants (ref.) | 3.2 (6.6) | 0 (ref.) | — | 0 (ref.) | — | 0 (ref.) | — | 0 (ref.) | — |
| Fat mass [%] (n = 2079) | |||||||||
| Antidepressants prior to baseline | |||||||||
| Number of compounds | — | −0.01 | (−0.18, 0.17) | −0.04 | (−0.23, 0.15) | −0.11 | (−0.30, 0.09) | −0.09 | (−0.29, 0.11) |
| Antidepressants during follow-up | |||||||||
| Any antidepressants | 2.5 (5.8) | 0.37 | (−0.10, 0.84) | 0.39 | (−0.13, 0.91) | 0.30 | (−0.25, 0.84) | 0.18 | (−0.38, 0.75) |
| No antidepressants (ref.) | 2.1 (5.7) | 0 (ref.) | — | 0 (ref.) | — | 0 (ref.) | — | 0 (ref.) | — |
Model 1 adjusted for socio-demographic characteristics (sex, age, socio-economic status, living alone during follow-up), early physical and sexual abuse, adiposity marker levels at baseline, behavioral factors (physical inactivity, smoking status, number of alcohol drinks per week) during follow-up, anxiety disorders and illicit drug dependence during follow-up, possibly weight gain inducing medication (other than antidepressants) during follow-up, and length of follow-up.
Model 2 = model 1 additionally adjusted for major depressive disorder (MDD) subtypes at baseline and during follow-up and current vs. remitted MDD status at follow-up.
Model 3 = model 2 additionally adjusted for severity during follow-up (number of symptoms of most severe major depressive episode (MDE), time spent in MDE, global assessment functioning (GAF) score, suicidality, hospitalization, psychotic features), and relatives with MDD.
SD standard deviation, 95%CI 95% confidence interval. ref. reference group.
aEach model adjusted for age, sex, and adiposity marker at baseline.
* p < 0.05, ** p < 0.01, *** p < 0.001.
Significant results are indicated in bold.